Focus Stocks
Forest Laboratories - Traders Waiting for Entry
Published on Monday, 28 November 2011 17:33 Written by Christian Paolinetti
New York, November 28th (TradersHuddle.com) - Shares of Forest Laboratories, Inc. (NYSE:FRX) closed the trading
day higher by $0.52 or 1.82% from its previous close. Forest Laboratories' shares price action formed what is considered to be a
doji close, where the open and close prices are very close to each other, mainly signaling an indecision between buyers and sellers.
Forest Laboratories, Inc. (NYSE:FRX) develops, manufactures, and sells branded and generic forms of ethical drug products. The Company also manufactures non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses.
Forest Laboratories' current stock range is defined by a trough, which marks calculated support at $28.56 and by a peak that marked the resistance point at $31.77. These levels are closely watched by traders managing their positions.
Traders wanting to establish a position in Forest Laboratories or traders that are already holding the stock can use the doji close to their advantage, since the pattern present a short term pause in the stock's price action. This pause results in an entry point for traders depending of which way the stock resolves this short term indecision.
Doji are important candlesticks that provide information on their own and as components in a number of important patterns. Doji form when a security's open and close are virtually equal. The length of the upper and lower shadows can vary and the resulting candlestick looks like a cross, inverted cross or plus sign. Alone, doji are neutral patterns.
Any bullish or bearish bias is based on preceding price action and future confirmation. In the case of Forest Laboratories, given that the stock finished the session higher, bulls should monitor their positions for confirmation that stock will continue higher by taking today's intraday high. Below a Doji illustration:

Related Articles
- Forest and Almirall to Present Aclidinium Bromide Clinical Data at the American Thoracic Society (ATS) International Conference
- Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association (APA) Annual Meeting
- New Ratings ( FRX, NEPT, PDCO )
- Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients with Major Depressive Disorder
- Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012
- Forest Laboratories, Inc. to Host Investor Meeting to Review Company’s Late-Stage Product Development Pipeline and Commercialization Strategy
- Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2012 Earnings Per Share of $0.72 Including $0.06 Per Share of Acquisition Amortization
- Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2012 Fourth Quarter Earnings
- Forest Laboratories, Inc. Announces Buyout of Bystolic Royalties from Janssen Pharmaceutica NV
- Forest Laboratories and Almirall Announce FDA has Extended the Review Period for Aclidinium Bromide
Related Partner Headlines
- Think Like the Father of Value Investing - TheStreet.com
- Notable Call Options Activity in Forest Laboratories - Benzinga
- Forest Laboratories and Pierre Fabre Medicament Announce Positive Phase III Results For Levomilnacipran in Patients with Major Depressive Disorder - Benzinga
- From Earlier: Forest Laboratories, Inc. and Gedeon Richter Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia - Benzinga
- From Earlier: Forest Laboratories Receives European Marketing Approval for Colobreathe Dry Powder Inhaler - Benzinga
- From Earlier: Forest and Almirall Announce Positive FDA Advisory Committee's Recommendation for Approval of Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease - Benzinga
- Analysts' Actions: GOOG, FRX, JBHT, KSU - TheStreet.com
- Forest Labs Posts Weak Quarter - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
-
Only 'Modest Contagion' for U.S. Banks - TheStreet.com -
10 Cheapest Sports Cars of 2012 - TheStreet.com -
Insiders Trading WWWW, LVLT, FCVA, VR - TheStreet.com -
A Broken Market - TheStreet.com -
JPMorgan Chase-ened - TheStreet.com -
Upgrades Roundup: Acxiom, Enersis - TheStreet.com -
Buy Nokia, Prepare RIM's Grave - TheStreet.com -
Grasping Shifts in Earnings Surprises - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,369.38 Trade time:4:02PM EDT Value change:▼73.11 (-0.59%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,295.22 Trade time:4:33PM EDT Value change:0.00 (0.00%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,778.79 Trade time:5:16PM EDT Value change:0.00 (0.00%)In The Wires
-
Industrial Nanotech, Inc. Announces Successful Installation of Initial Projects with Major U.S. Manufacturers -
BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc. -
Digital Hands Receives WBENC Certification -
Gladstone Investment Corporation Announces Earnings Call and Webcast Information -
Market Rates Insight's New Integrated Study on Service Fees Reveals "Lifestyle Financial Services" Will Pay Off for Financial Institutions -
Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com -
Ubiquiti Networks Launches the US Litigation Phase of Its Anti-Counterfeiting Efforts -
MDU Resources Subsidiary Purchases Interest in Bakken Oil and Natural Gas Midstream Assets









